EN
Home/Canada/Blog/Which generic semaglutide pens were recalled in Canada in 2026, and what should you do?
CACanada Side effects and safety

Which generic semaglutide pens were recalled in Canada in 2026, and what should you do?

Every Health Canada recall of generic semaglutide in 2026, the lot numbers, what went wrong, and what Health Canada tells you to do. Checked 12 October 2026.

GLP Guidebook teamPublished 12 Oct 20269 min read14 sourcesWritten from published sources

Written for Canada. Reading from India? India version

The short answer

Three Type II recalls, all in August 2026: one Dr. Reddy’s lot had a 4 mg pen in a 2 mg box (12 August), eight Dr. Reddy’s lots had an impurity out of specification (27 August), and one Apo-Semaglutide lot may give 2 mg instead of 0.25 or 0.5 mg (27 August). Check your lot, and don’t stop without advice.

Key takeaways

  • Health Canada posted three recalls of generic semaglutide in August 2026, two for Dr. Reddy’s Semaglutide Injection and one for Apo-Semaglutide.1,2,3
  • Apo-Semaglutide lot 7000599A may deliver 2 mg instead of the expected 0.25 or 0.5 mg, which is 4 to 8 times the intended dose.3
  • Eight Dr. Reddy’s lots were recalled on 27 August 2026 because “an impurity is out of specification”; Health Canada did not name the impurity.2
  • For every recall, Health Canada’s advice is to check your product and to consult your healthcare provider before you stop using it.1,2,3
  • Dr. Reddy’s also reported a shortage from 10 July 2026, caused by a manufacturing disruption.4
Before you go further
  • GLP‑1 medicines are prescription drugs in Canada. Nothing here is a reason to start, stop or switch one.5
  • We name brands and official prices as facts. We don’t recommend, rank or link to any brand, pharmacy, clinic or program.
  • Ozempic, its generics and Mounjaro are approved for type 2 diabetes. Using them for weight loss is off-label (outside the approved use).6,7
  • The risks are the same however you get the medicine: see our side effects guide.
On this page
  1. Which products and lots were recalled?
  2. How do I check whether my pen is affected?
  3. What should I do if my lot is on the list?
  4. What if I injected from the Apo-Semaglutide lot?
  5. What does “impurity out of specification” mean?
  6. How do I report a problem with my pen?
  7. Questions people ask
  8. How we researched this
  9. Sources

Which products and lots were recalled?

Three recalls, all classed Type II and all at the retail level, covering one Apotex lot and nine Dr. Reddy’s lot entries.1,2,3

DateProduct (DIN)LotsProblem
12 Aug 2026Dr. Reddy’s Semaglutide Injection, labelled 2 mg/pen (02567806)7000544CA 4 mg pen packed in a box labelled 2 mg
27 Aug 2026Dr. Reddy’s Semaglutide Injection (02567806 and 02567814)7000542, 7000543, 7000544, 7000545, 7000546, 7000624, 7000628, 7000629An impurity out of specification
27 Aug 2026Apo-Semaglutide, 2 mg/pen (02568020)7000599AMay show and deliver 2 mg instead of 0.25 or 0.5 mg

In date order. Sources: Health Canada recall notices, recalls-rappels.canada.ca, checked 12 October 2026.

Sources for the rows: the 12 August notice1, the Dr. Reddy’s impurity notice2 and the Apo-Semaglutide notice.3 We found no further generic semaglutide recall posted up to 12 October 2026.

The brand has had one too. In 2025, two Ozempic 1 mg lots (RZFFE55 and RZFFE56) were recalled because “glass cartridges may be cracked”.8

How do I check whether my pen is affected?

Compare the DIN and the lot number on your pack with the recall notice. If both match, your pen is affected.1,2,3

The DIN is the 8-digit Drug Identification Number on the label.9 The lot is the batch number. Each notice lists both.

  • Dr. Reddy’s: DIN 02567806 or 02567814, and one of lots 7000542 to 7000546, 7000624, 7000628 or 7000629 (and 7000544C).1,2
  • Apotex: DIN 02568020, lot 7000599A.3
  • Not sure? Your pharmacist can look up what was dispensed to you.

Brand Ozempic and the other generics are not in these 2026 recalls.1,2,3 Every generic and its status: generic semaglutide in Canada.

What should I do if my lot is on the list?

Health Canada says: check your product, and “consult your healthcare provider prior to discontinuing use of the affected product”.2,3

Each notice gives the same steps: check whether your product is affected, talk to your healthcare provider before stopping, contact the company with questions, and report any side effect to Health Canada.1,2,3

The reason not to stop on your own: semaglutide may be managing your blood sugar. Monographs warn that stopping it can raise blood sugar in people with type 2 diabetes.10 A pharmacist or prescriber can arrange a replacement.

Reading pathAlready taking a GLP‑1?

A short reading path for people already on one: doses, side effects, pens and what to check.

Open the path

What if I injected from the Apo-Semaglutide lot?

That lot may give 2 mg when 0.25 or 0.5 mg was set, 4 to 8 times the intended dose. Too much semaglutide can cause severe nausea, vomiting and low blood sugar.3,11

The Wegovy monograph says an overdose “may be associated with severe hypoglycemia, severe nausea and severe vomiting which could lead to dehydration”. There is no specific antidote, so care is supportive.11

If you think you took too much, call a poison centre on 1-844-POISON-X (1-844-764-7669), or 1-800-463-5060 in Quebec.12 For severe symptoms, call 911.

For the Dr. Reddy’s pen in the wrong box, Health Canada did not say how it could change a dose. Ask your pharmacist.1

RisksThe risks, in brief
  • Stomach effects. In the diabetes trials in Ozempic’s Canadian monograph, about 17 in 100 people on 0.5 mg felt sick (nausea), and 20 in 100 on 1 mg. On comparison treatments it was about 6 in 100.6
  • Gallstones. About 7 in 1,000 people on 0.5 mg and 11 in 1,000 on 1 mg, against 5 in 1,000 on comparison treatments.6
  • Pancreatitis (an inflamed pancreas): confirmed in 0.3 cases per 100 patient-years on Ozempic in the diabetes trials, against 0.2 on another GLP‑1 medicine and none on a dummy injection or other diabetes medicines. The warning sign is severe stomach pain that won’t go away, sometimes spreading to the back.6,11
  • Low blood sugar is more likely if you also take insulin or a sulfonylurea such as gliclazide.11
  • Thyroid. Semaglutide must not be used if you or a family member has had medullary thyroid cancer, or if you have MEN 2.6
Full detail in our side effects guide →
Get help now: call 911 or go to the nearest emergency department for severe stomach pain that won’t go away, with or without vomiting. It can be pancreatitis. Not sure? Call 811 to speak to a nurse in most provinces (Info-Santé 811 in Quebec).11,13

What does “impurity out of specification” mean?

It means a test result was outside the limit set for that product. Health Canada’s notice did not name the impurity or describe a health effect.2

The notice says only: “An impurity is out of specification in all lots of the affected products.”2 It is classed Type II, like the other two.2

Dr. Reddy’s had already reported a shortage on 10 July 2026, after a manufacturing disruption. Alberta postponed its lowest-cost pricing for semaglutide because of it.4 Health Canada’s database still listed both Dr. Reddy’s pens as marketed on 12 October 2026.5

How do I report a problem with my pen?

Report side effects to Health Canada’s Canada Vigilance Program, online or by phone on 1-866-234-2345. Anyone can report.14,11

Health Canada says “anyone can report a side effect”, even if you aren’t sure the medicine caused it.14 Reports help it spot safety problems.

Tell your pharmacist too, and keep the pen and box. The recall notices list the company’s contact for questions.1,3

Questions people ask

Was my Dr. Reddy’s semaglutide pen recalled?

Only if the DIN is 02567806 or 02567814 and the lot is 7000542, 7000543, 7000544, 7000544C, 7000545, 7000546, 7000624, 7000628 or 7000629.1,2

Was Apo-Semaglutide recalled?

One lot was: 7000599A of the 2 mg/pen (DIN 02568020), which may deliver 2 mg instead of 0.25 or 0.5 mg.3

Should I stop using a recalled pen?

Health Canada advises consulting your healthcare provider before you stop using the affected product.2,3

Was Ozempic recalled?

Not in these 2026 recalls. In 2025, two Ozempic 1 mg lots, RZFFE55 and RZFFE56, were recalled for possibly cracked glass cartridges.8

Where can I see new recalls?

Health Canada posts every recall on recalls-rappels.canada.ca. All three 2026 generic semaglutide recalls were Type II, at the retail level.1,2,3

How we researched this

We read each Health Canada recall notice on recalls-rappels.canada.ca and searched for further semaglutide recalls up to 12 October 2026. Supply details come from Alberta Blue Cross bulletins; product status from Health Canada’s Drug Product Database.

Recalls can be added at any time. Check the recalls site for anything newer.

Before you move on

  • Find the DIN and lot on your pack.
  • Compare them with the notices above.
  • Don’t stop without talking to your prescriber or pharmacist.
  • Keep a recalled pen and its box until you’ve asked.
  • Report any side effect to Canada Vigilance.
Already taking oneSide effects and risksGetting a prescription, and the medicines

More from the Canada blog

CACanadaWhich generic versions of Ozempic and Wegovy are approved in Canada?CACanadaHow do you spot fake Ozempic or “research peptide” GLP‑1s in Canada?CACanadaHow much do Ozempic, Wegovy, Mounjaro and Zepbound cost in Canada?
About GLP Guidebook

The monthly Canada update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write

Was this post easy to understand?

Sources

  1. Health Canada recall. Semaglutide Injection (Dr. Reddy’s), DIN 02567806, lot 7000544C: “The affected lot contains a 4 mg pen but is labelled as a 2 mg pen.” Type II, retail level. 12 August 2026. Link
  2. Health Canada recall. Semaglutide Injection (Dr. Reddy’s), DINs 02567806 and 02567814, lots 7000542, 7000543, 7000544, 7000545, 7000546, 7000624, 7000628 and 7000629: “An impurity is out of specification in all lots of the affected products.” Type II, retail level. 27 August 2026. Link
  3. Health Canada recall. Apo-Semaglutide (2 mg/pen), DIN 02568020, lot 7000599A: may “display a 2 mg dose in the dose window and deliver a 2 mg dose instead of the expected 0.25 mg or 0.5 mg dose.” Type II, retail level. 27 August 2026. Link
  4. Alberta Blue Cross. Pharmacy Benefact 1330, July 2026 (generic semaglutide added to the Alberta Drug Benefit List from 1 July 2026, interchangeable with Ozempic; Dr. Reddy’s shortage reported 10 July 2026; LCA pricing postponed). PDF
  5. Health Canada. Drug Product Database: status records for every semaglutide product (Ozempic, Rybelsus, Wegovy, Plosbrio, Poviztra; generics from Dr. Reddy’s, Apotex, Aspen and Sandoz, and Sevmia). Searched 12 October 2026. Link
  6. Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, 13 July 2026 (produced by recombinant DNA technology in yeast; 2, 4 and 8 mg pens; indications; adverse reactions table; pancreatitis; contraindications). PDF
  7. Eli Lilly Canada. Mounjaro (tirzepatide injection) Product Monograph, date of authorization 23 June 2026 (type 2 diabetes in adults and in ages 10 to under 18; single-dose pen, vial and 4-dose KwikPen; storage). PDF
  8. Health Canada recall. Ozempic solution, DIN 02471469, lots RZFFE55 and RZFFE56: “Glass cartridges may be cracked in the affected lot.” Type II. Posted 30 June 2025, updated 31 October 2025. Link
  9. Health Canada. Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products (public advisory: buy only from a licensed pharmacy; check the eight-digit DIN; risks; misused logos and fake endorsements). Updated 21 January 2026. Link
  10. Apotex. Sevmia (semaglutide injection) Product Monograph, date of authorization 29 June 2026 (“SEVMIA can be prescribed only for 1 mg once weekly dosing. Alternative products are needed to achieve doses of Semaglutide Injection exclusive of the 1 mg dose”; 1 pen of 4 doses; storage). PDF
  11. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, date of authorization 2 October 2026 (indications; dose escalation; STEP 1–3 results and adverse reactions; pancreatitis, gallbladder, kidney and pregnancy warnings; storage). PDF
  12. Health Canada. Canada launches new toll-free 1-844-POISON-X number for poison centres (Quebec: 1-800-463-5060). News release, 20 March 2023. Link
  13. Heart and Stroke Foundation of Canada. Medical services by phone (811 in most provinces and Yukon; Info-Santé 811 in Quebec; other numbers in Manitoba, the Northwest Territories and Nunavut). Checked 12 October 2026. Link
  14. Health Canada. Adverse reaction and medical device problem reporting (Canada Vigilance Program; “Anyone can report a side effect”). Checked 12 October 2026. Link

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write